Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aventis Alvesco For Asthma Is One Of Five NDA/BLA Filings Planned For 2003

Executive Summary

Aventis is planning a third quarter NDA filing for the asthma therapy Alvesco, one of up to five novel agents the company expects to reach the filing stage by early 2004

You may also be interested in...



Aventis Plans To Launch Genasense, Ketek and Apidra In 2004

The launch of Genasense will be a key step in Aventis' plans to build its oncology franchise, Chief Operating Officer Richard Markham said Jan. 13 during the J.P. Morgan health care conference in San Francisco

Aventis Plans To Launch Genasense, Ketek and Apidra In 2004

The launch of Genasense will be a key step in Aventis' plans to build its oncology franchise, Chief Operating Officer Richard Markham said Jan. 13 during the J.P. Morgan health care conference in San Francisco

Aventis abandons cariporide

Aventis will not seek regulatory approval for cariporide, company says May 16. Phase III trial for cardiovascular drug candidate was halted in July 2002 by data safety monitoring board (1"The Pink Sheet" Feb. 24, p. 24)...

Related Content

UsernamePublicRestriction

Register

GB140150

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel